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Abstract
Background: Cutaneous squamous cell carcinoma (SCC) is associated with underlying immunosuppression, so it
may be a prognostic marker in patients with subsequent cancer. We therefore conducted a nationwide
population-based Danish cohort study to evaluate whether a history of cutaneuos SCC has prognostic impact in
patients with one of the following index cancers: non-Hodgkin’s lymphoma (NHL), or cancer of the lung, colon,
rectum, breast, or prostate.
Methods: We used Danish medical databases, which cover the entire Danish population of 5.6 million inhabitants
and linked them using the unique personal identification number assigned to all Danish residents. From 1982
through 2003, we identified 745 index cancer patients with and 79,143 without previous cutaneous SCC. Using Cox
proportional hazards regression, we calculated adjusted mortality rate ratios (MRRs) with 95% confidence intervals
(CIs).
Results: Overall, previous SCC was associated with an increased mortality of cancer (MRR 1.13, 95% CI: 1.04-1.23).
When examining index cancers separately, increased MRRs were found for cancer of the lung (MRR 1.23, 95% CI:
1.05-1.43), colon (MRR 1.13, 95% CI: 0.92-1.40), rectum (MRR 1.29, 95% CI: 1.00-1.67), breast (MRR 1.09, 95% CI: 0.82-
1.43), and NHL (MRR 1.09, 95% CI: 0.81-1.47), but not for prostate cancer (MRR 0.99, 95% CI: 0.83-1.18).
Conclusions: Our results suggest that previous cutaneous SCC is associated with poor prognosis of some cancers.
This finding stresses the importance of adherence to the existing recommendations of screening, diagnosis, and
treatment of cancer in patients with a history of SCC.
Background
Non-melanoma skin cancer (NMSC)–basal cell carci-
noma (BCC) and squamous cell carcinoma (SCC) [1]–is
associated with an increased risk of developing both
subsequent NMSC [2] and other malignancies compared
with the general population [3-5]. Common risk factors
have been proposed as the cause, for example, ultravio-
let radiation (UVR) and immune incompetence [6,7]. In
particular, cutaneous SCC is known to be associated
with immunosuppression [6,8,9], but whether it is a reli-
able marker for reduced immune competence that could
explain these findings is unknown. Overall, five studies
have found higher mortality rates in cancer patients
with previous SCC [4,10-13], which also could be
explained by reduced immune competence. None of the
studies, however, included information on important
factors such as cancer treatments and comorbidity.
Therefore, taking these factors into account, while
focusing on the most common types of cancers, we con-
ducted a nationwide population-based Danish cohort
study to examine whether a history of cutaneous SCC
has prognostic impact in patients with a subsequent
diagnosis of one of the following index cancers: non-
Hodgkin’s lymphoma (NHL), or cancer of the lung,
colon, rectum, breast, or prostate. * Correspondence: saj@dce.au.dk
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The current study was conducted using Danish medical
databases, which cover the entire Danish population of
5.6 million inhabitants [14]. Accurate and unambiguous
linkage of all registries was possible using the unique
personal identification number assigned to all Danish
residents [14].
Study cohort
From the Danish Cancer Registry (DCR), we identified
all patients aged 20 to 99 years with a first diagnosis of
an index cancer from 1982 through 2003 occurring in
the month after a cutaneous SCC diagnosis or later.
Because of the rarity of a history of SCC of the skin
among cancer patients, we chose to focus on the most
common types of cancer (cancer of the lung, colon,
rectum, breast, or prostate). In addition, we included
NHL because of its link to immune function and for
comparison with previous studies on the topic
[4,10-13]. The DCR contains records of all incident
malignant neoplasms in Denmark since 1943 and pro-
vides details on morphology, histology, stage of cancer
at the time of diagnosis, and initial cancer therapies
within four months of diagnosis [15]. All diagnostic
codes used in this study are provided in the Additional
file 1: Table S1.
Given abundant data in the DCR, in combination with
the fact that our focus was mortality following the most
common cancers in Denmark, we decided that for each
selected cancer patient with a history of cutaneous SCC,
we would randomly choose 100 patients with the same
index cancer but without preceding SCC of the skin.
Initially, we aimed to include human immunodefi-
ciency virus (HIV) diagnosis and previous solid organ
transplantation as a measure of immune function, but
due to a small numbers of patients in these categories,
we excluded all patients with HIV (n = 4) or previous
solid organ transplantation (n = 45). Due to a small
numbers of patients with a history of cutaneous SCC in
age groups 20-29 years (n = 0), 30-39 years (n = 1) and
40-49 years (n = 3), we chose not to include these age
groups in the analysis.
Mortality data
We identified all-cause death using the Danish Civil
Registration System (established on April 2, 1968),
which is updated daily and records all changes in vital
status, date of death, and migration [14]. We identified
cancer-specific death using the Danish Registry of
Causes of Death, which contains information on all
deaths in Denmark since 1943 [16]. We used the cause
of death reported on the death certificate grouped into
14 categories as defined by the National Board of Health
[17]. Each death certificate includes one underlying, and
up to three immediate causes of death [16]. If any of
these causes were a malignancy, we used that as the
cause of death.
Comorbidity
We obtained information on comorbid diseases from
The Danish National Patient Registry, which provides
information about all inpatient admissions to somatic
hospitals since 1977, and all outpatient and emergency
admissions since 1995 [18]. We categorized the level of
comorbidity by using the Charlson Comorbidity Index
( C C I )[ 1 9 ] ,a ne x t e n s i v e l ys t u d i e da n dv a l i d a t e di n s t r u -
ment used to predict risk of death from comorbid dis-
eases [19,20]. We computed the CCI score for each
study subject based on the complete hospital discharge
history for at least 5 years before index cancer diagnosis,
and grouped it into three levels: Low = 0, medium = 1-
2, and high > 3.
According to our hypothesis cutaneous SCC is asso-
ciated with poor prognosis in cancer patients due to
underlying immune incompetence. We would therefore
expect diseases involving the immune system or immu-
nosuppressive therapies to be more frequent in patients
with a history of SCC. To examine this, we also
included a list of autoimmune diseases, as a proxy mea-
sure of immune function.
Statistical analysis
To include information on initial cancer therapies, fol-
low-up started four months after index cancer diagnosis,
and continued until death, emigration, diagnosis of cuta-
neous SCC in patients without that history at diagnosis
of the index cancer, end of follow-up (31 December
2008), or a maximum of 10 years, whichever came first.
130 patients who had died or were censored by start of
follow-up were not included in the analysis.
Initially, we computed the frequency and proportion
of covariates, number of deaths and amount of accumu-
lated person-time within index cancer cohorts, stratified
by history of cutaneous SCC. Then, we calculated crude
mortality rate ratios (MRRs) with 95% confidence inter-
vals (CIs) associating previous cutaneous SCC with
mortality.
We used Cox proportional hazard regression to esti-
mate MRRs with 95% CIs for index cancer patients with
a history of cutaneous SCC compared with index cancer
patients without such history adjusting for age group
(50-69, 70-79, 80-89, 90-99 years), a variable that calcu-
lated the midpoint of the age group divided by exact age
for each individual, gender, CCI (low, medium, high),
calendar period (1982-1986, 1987-1991, 1992-1996,
1997-2001, 2002-2003), history of autoimmune disease
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missing), and the following index cancer treatments: no/
symptomatic treatment, chemotherapy, radiation ther-
apy, hormone therapy, operation, and other/missing
treatment. To examine the presence of effect modifica-
tion, we stratified the model on age groups, gender,
CCI, and history of autoimmune disease. We also strati-
fied mortality rates on time between SCC and index
cancer diagnoses. Next, we fitted a reduced model with-
out adjustment for stage and treatment since we
hypothesized that they may be on the causal pathway
l i n k i n gc u t a n e o u sS C Ct op o o rp r o g n o s i s .T h a ti s ,
decreased immune surveillance may cause faster pro-
gression of the cancers and thereby more advanced
stage at diagnosis, which in turn affects the choice of
treatment. In a subanalysis, we found no substantial dif-
ference between the phenotypic variant chronic lympho-
cytic leukemia and other NHL types and therefore
report the pooled results. All analyses were performed
for both all-cause and cancer-specific death within each
index cancer and overall. 476 persons, who were regis-
tered as dead in the CRS, but not in the Danish Registry
of Causes of Death, were censored at the date of death
in analysis for death from cancer. They did not differ
from the total population with regard to exposure.
Finally, we assessed the assumption of proportional
hazards by graphical examination of log-log plots against
log-time and found it not to be violated.
After 2003, information on cancer treatments was not
available. In a subanalysis, we excluded treatment from
the model, which allowed us to increase the enrollment
period from 1982 through 2008, and thereby, include
more patients. Lung and breast cancer was left out from
this analysis, since their results were affected by adjust-
ment for cancer treatment.
If cutaneous SCC is diagnosed shortly after an index
cancer it could still be a marker of poor prognosis, caus-
ing us to underestimate the effect when including such
patients in the comparison group. We therefore
repeated our analysis after excluding patients receiving a
diagnosis of cutaneous SCC within two years after index
cancer diagnosis. This exclusion did not change the
estimates.
All analyses were performed using STATA
® software
(version 11.0, STATA, College Station, TX). Because the
data are obtained from existing medical registries there
are no considerable ethical aspects of this study and the
study was approved by the Danish Data Protection
Agency (Registration number: 2007-58-0010).
Results
Patient characterstics
We included 745 index cancer patients with and 79,143
without a history of cutaneous SCC. Patients with
previous cutaneous SCC were older at index cancer
diagnosis, were more frequently men, had their index
cancer diagnosis in a more recent calendar period, and
had higher comorbidity (Table 1). Furthermore, SCC
patients had more frequently missing stage and treat-
ment information, more often received no or sympto-
matic treatment (except in breast cancer) and had more
frequently a history of any autoimmune disease (see
Additional file 2: Table S2).
Mortality
We observed shorter survival time among those with a
history of cutaneous SCC within all index cancer
groups, with an overall median survival time of 1.93
years (lower quartile 0.58 years; upper quartile 5.09
years) in SCC patients and 2.57 years (lower quartile
0.74 years; upper quartile 6.54 years) in patients without
SCC (Additional file 2: Table S2). The most frequent
cause of death was malignancy. We were not able to
distinguish between NMSC subtypes for cause of death,
but a total of 22 persons died of NMSC (2.95% of
deaths) among the exposed and 31 (0.04% of deaths)
among the unexposed patients.
Overall, a history of cutaneous SCC was associated with
an increased relative rate of death from cancer (MRR 1.13,
95% CI: 1.04-1.23) (Table 2). When examining index can-
cers separately, increased MRRs were found for cancer of
the lung (MRR 1.23, 95% CI: 1.05-1.43), colon (MRR 1.13,
95% CI: 0.92-1.40), rectum (MRR 1.29, 95% CI: 1.00-1.67),
breast (MRR 1.09, 95% CI: 0.82-1.43), and NHL (MRR
1.09, 95% CI: 0.81-1.47). There was no increased rate of
dying of prostate cancer (MRR 0.97, 95% CI: 0.81-1.15).
The impact of covariates on the mortality rate of cancer is
shown in Table 3. The stratified analysis revealed no effect
modification (data not shown).
Impact of prognostic factors
After including all other covariates, adding comorbidity
to the model resulted in a 7% attenuation of the MRR
for NHL, but had no effect in the remaining cancers.
Adjusting for stage did not affect the results, while
adjusting for cancer treatment had an impact in lung
and breast cancer in the sense that it raised their MRRs
by approximately 7%.
Increasing the enrollment period to 2008 resulted in
no substantial change for prostate (MRR 1.03, 95% CI:
0.88-1.21) and colon cancer (MRR 1.10, 95% CI: 0.90-
1.33), while an increase was observed for rectal cancer
(MRR 1.43, 95% CI: 1.13-1.81) and NHL (MRR 1.23,
(95% CI: 0.96-1.57).
Discussion
We found that a history of cutaneous SCC was asso-
ciated with a moderately increased mortality rate
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tum, breast, and NHL, but not in survivors of prostate
cancer. The present study is the first to examine this
association taking into account comorbidity and index
cancer treatments. Adjustment for these factors had no
substantial effect on our results, so it is unlikely that
they have introduced major confounding in previous
studies.
Table 1 Selected characteristics of persons diagnosed with an index cancer (cancer of the lung, colon, rectum, breast,
prostate, or non-Hodgkin’s lymphoma (NHL)) in Denmark 1982-2003, by history of cutaneous squamous cell
carcinoma (SCC)
Characteristics Lung cancer Colon cancer Rectal cancer
+ SCC (%) - SCC (%) + SCC (%) - SCC (%) + SCC (%) - SCC (%)
Total 175 18,662 138 14,647 77 7,089
Gender
Men 140 (80) 11,673 (63) 87 (63) 6,592 (45) 60 (78) 4,086 (58)
Women 35 (20) 6,989 (37) 51 (37) 8,055 (55) 17 (22) 3,003 (42)
Age group (years)
a
50-69 49 (28) 11,471 (61) 23 (17) 5,968 (41) 15 (19) 3,383 (48)
70-79 82 (47) 5,895 (32) 48 (35) 5,479 (37) 34 (44) 2,487 (35)
80-89 41 (23) 1,241 (6.7) 59 (43) 2,958 (20) 22 (29) 1,107 (16)
90-99 3 (1.7) 55 (0.3) 8 (5.8) 242 (1.7) 6 (7.8) 112 (1.6)
Calendar period
b
1982-1986 19 (11) 3,798 (20) 12 (8.7) 3,023 (21) 11 (14) 1,565 (22)
1987-1991 25 (14) 3,866 (21) 26 (19) 3,219 (22) 15 (19) 1,557 (22)
1992-1996 47 (27) 4,101 (22) 35 (25) 3,324 (23) 22 (29) 1,578 (22)
1997-2001 66 (38) 4,832 (26) 49 (36) 3,549 (24) 17 (22) 1,683 (24)
2002-2003 18 (10) 2,065 (11) 16 (12) 1,532 (10) 12 (16) 706 (10)
Comorbidity level
c
Low 81 (46) 12,081 (65) 81 (59) 10,806 (74) 54 (70) 5,477 (77)
Moderate 69 (39) 5,306 (28) 47 (34) 3,221 (22) 18 (23) 1,365 (19)
High 25 (14) 1,275 (6.8) 10 (7.3) 620 (4.2) 5 (6.5) 247 (3.5)
Breast cancer Prostate cancer NHL
d
+ SCC (%) - SCC (%) + SCC (%) - SCC (%) + SCC (%) - SCC (%)
Total 113 10,418 186 21,364 56 6,963
Gender
Men - - 186 (100) 21,364 (100) 46 (82) 3,896 (56)
Women 113 (100) 10,418 (100) - - 10 (18) 3,067 (44)
Age group (years)
a
50-69 25 (22) 6,298 (60) 18 (9.7) 7,014 (33) 11 (20) 3,253 (47)
70-79 38 (34) 2,569 (25) 83 (45) 9,423 (44) 21 (38) 2,492 (36)
80-89 40 (35) 1,369 (13) 77 (41) 4,61 (22) 20 (36) 1,130 (16)
90-99 10 (8.9) 182 (1.8) 8 (4.3) 308 (1.4) 4 (7.1) 88 (1.3)
Calendar period
b
1982-1986 6 (5.3) 1,866 (18) 20 (11) 3,825 (18) 8 (14) 1,261 (18)
1987-1991 18 (16) 2,029 (19) 30 (16) 4,562 (21) 10 (18) 1,392 (20)
1992-1996 28 (25) 2,469 (24) 39 (21) 4,333 (20) 13 (23) 1,659 (24)
1997-2001 44 (39) 2,806 (27) 69 (37) 5,700 (27) 15 (27) 1,876 (27)
2002-2003 17 (15) 1,248 (12) 28 (15) 2,944 (14) 10 (18) 775 (11)
Comorbidity level
c
Low 77 (68) 8,406 (81) 106 (57) 14,554 (68) 28 (50) 5,183 (74)
Moderate 29 (26) 1,667 (16) 58 (31) 5,558 (26) 20 (36) 1,517 (22)
High 7 (6.2) 345 (3.3) 22 (12) 1,252 (5.9) 8 (14) 263 (3.8)
aAge at index cancer diagnosis
bCalendar period of index cancer diagnosis
cThree levels of comorbidity were defined based on Charlson index scores of 0 (low), 1-2 (medium), and > 2 (high)
dIncludes the phenotypic variant chronic lymphocytic leukemia
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find an overall increased mortality rate in cancer
patients with a history of cutaneous SCC. When exam-
ining index cancer types individually, there are, however,
some inconsistencies with previous studies. Askling et
al., Kahn et al., and Nugent et al. included prostate and
breast cancer in their studies. All three studies found a
19 to 45% increased mortality rate among breast cancer
patients with a history of cutaneous SCC. In compari-
son, we found a 9% increase. In contrast to Askling et
al. and Kahn et al., we found no increased rate of death
from prostate cancer. For the remaining index cancers,
the finding of a poorer prognosis in patients with pre-
vious cutaneous SCC is consistent across studies
[4,10-13]. In both colon and rectal cancer, only Kahn et
al. found no increase in the mortality rate. This differ-
ence may be explained by the fact that they did not dif-
ferentiate between NMSC subtypes, since Hjalgrim et al.
and Nugent et al. showed that MRRs for these cancers
were lower for BCC than SCC patients.
An association between a history of cutaneous SCC
and a poor prognosis may be explained by an underlying
immunodeficiency. Cumulative UVR exposure, the
major risk factor of SCC of the skin [1], is especially
interesting since UVR induces cellular immune incom-
petence [6]. This reduced immune function may be
observed both locally and systemically and it is more
pronounced in patients with previous skin cancer than
in the general population [6,21]. We therefore hypothe-
size that cutaneous SCC is a marker of underlying
immunosuppression that compromises the patient’s nor-
mal immune surveillance against nascent tumor cells
resulting in poor prognosis of subsequent cancer. NHL
is interesting from this immunologic perspective, given
its strong association with immune function. Hence, we
would have expected a greater increase compared with
the other cancers that are not as strongly related to
immune function. However, the imprecision of our
estimates, especially for NHL, limit us from concluding
on any substantial differences between cancers. Further-
more, alternative explanations such as field canceriza-
tion due to an unidentified carcinogen may also explain
our findings.
The low number of observations limited the analysis
of associations for subtypes of autoimmune diseases,
Table 2 Mortality rate ratios for death from cancer,
associated with prior cutaneous squamous cell carcinoma
in persons diagnosed with cancer of the lung, colon,
rectum, breast, prostate, or non-Hodgkin’s lymphoma
(NHL) in Denmark 1982-2003
Unadjusted
MRR (95% CI)
Adjusted
a
MRR (95% CI)
Lung cancer 1.27 (1.09-1.48) 1.23 (1.05-1.43)
Colon cancer 1.31 (1.06-1.61) 1.13 (0.92-1.40)
Rectal cancer 1.53 (1.19-1.98) 1.29 (1.00-1.67)
Breast cancer 1.37 (1.05-1.81) 1.09 (0.82-1.43)
Prostate cancer 1.11 (0.93-1.32) 0.97 (0.81-1.15)
NHL
b 1.46 (1.09-1.96) 1.09 (0.81-1.47)
Overall 1.24 (1.14-1.35) 1.13 (1.04-1.23)
CI: confidence interval
aAll estimates are adjusted for age group, age group divided by exact age for
each individual, gender, Charlson comorbidity index (low, medium, high),
calendar period (1982-1986, 1987-1991, 1992-1996, 1997-2001, 2002-2003), a
history of any autoimmune disease (yes/no), stage (localized, regional, distant,
or unknown/missing), and the following index cancer treatments: no/
symptomatic, chemotherapy, radiation therapy, hormone therapy, operation,
and other/missing treatment
bIncludes the phenotypic variant chronic lymphocytic leukemia
Table 3 Mortality rate ratios and 95% confidence
intervals for death from cancer associated with various
characterstics in persons diagnosed with cancer of the
lung, colon, rectum, breast, prostate, or non-Hodgkin’s
lymphoma (NHL)
a in Denmark 1982-2003
History of cutaneous squamous cell cacrcinoma 1.13 (1.04-1.23)
Male gender
b 1.27 (1.24-1.29)
Age group (years)
c
70-79 1.29 (1.26-1.31)
80-89 1.61 (1.57-1.65)
90-99 2.32 (2.15-2.50)
Age difference
d 0.98 (0.98-0.98)
Calendar period
e
1987-1991 0. 97 (0.95-1.00)
1992-1996 0.87 (0.85-0.89)
1997-2001 0.65 (0.63-0.66)
2002-2003 0.49 (0.47-0.51)
Comorbidity level
f
Moderate 1.22 (1.19-1.24)
High 1.43 (1.37-1.49)
Stage
g
Regional 2.28 (2.22-2.33)
Distant 3.35 (3.26-3.44)
Unknown/missing 1.24 (1.21-1.28)
Treatment of index cancer
No/symptomatic 0.93 (0.89-0.96)
Chemotherapy 1.01 (0.98-1.05)
Radiation 1.19 (1.16-1.23)
Operation 0.45 (0.44-0.47)
Hormone therapy 0.57 (0.55-0.59)
Missing/other 0.59 (0.56-0.62)
Any autoimmune disease
h 1.07 (1.02-1.11)
aIncludes the phenotypic variant chronic lymphocytic leukemia
bReference is women
cAge reference is 50-69 years
dContinuous variable calculated as the midpoint of the age group divided by
exact age for each individual
eReference is the time period 1982-1986
fReference is comorbidity level low
gReference is localized stage
hReference is no autoimmune disease
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severity and type of autoimmune disease “ah i s t o r yo f
any autoimmune disease” may be an imperfect reflection
of immunosuppression. Furthermore, information on a
h i s t o r yo fa u t o i m m u n ed i s e a s em a yb eu n d e r r e p o r t e d ,
especially in the mild cases. These limitations prevent us
from ruling out a differential effect in people with auto-
immune disease.
Our study has several limitations. Even though the
Danish Cancer Registry is close to complete for most
malignancies [15], NMSC registration is probably under-
reported [5,22] due to the high incidence of NMSCs
b u r d e n i n gt h es y s t e m sa n dt h eh i g hc u r er a t et h a tm a y
cause clinicians to consider it trivial, especially in
patients with comorbidity [23]. We do not, however,
find it likely that mortality of a malignancy occurring
later in time would affect misclassification of cutaneous
SCC.
Misclassification of cause of death may be possible.
The Danish Registry of Causes of Death has varying
validity for different causes of death, although it is
almost complete for cancer deaths [16,24,25]. The major
problem with the registry is that the sequence of events
may not be accurate [25]. To avoid this problem, we
considered cause of death to be cancer if any cause on
the death certificate was a malignancy. Moreover, we
repeated all analyses for all-cause death by using the
civil registration system, which is virtually complete
[14]. This change in outcome slightly attenuated the
results, but they were not substantially different from
the cancer-specific MRRs.
Surveillance bias might have affected our results if
preceding SCC of the skin is associated with increased
medical surveillance leading to earlier diagnosis, and
hence, better prognosis. Th i sb i a sw o u l dh a v ew o r k e d
against the direction of the observed association, so it
cannot explain the results. In addition, a Danish study
of NMSC and risk of subsequent cancer found no evi-
dence of more intensive surveillance for internal malig-
nancies [5], which is in accordance with Danish
guidelines on follow-up in patients with cutaneous SCC
[26]. Moreover, we found no substantial difference
between mortality rates stratified on time between SCC
and index cancer diagnoses.
Conclusions
The present study is the first to examine mortality in
cancer patients with previous SCC of the skin, taking
comorbidity and cancer treatments into account. Pre-
vious studies have found an increased risk of cancer in
SCC patients [3-5] and our study extends this to also
include an increased mortality of some types of cancer.
Given the increasing incidence of cutaneous SCC [1],
these results stress the importance of adherence to the
existing recommendations of screening, diagnosis, and
treatment of cancer in patients with a history of cuta-
neous SCC.
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